文献速递白血病

ETV6::RUNX1白血病治疗反应的基因组决定因素

Genomic determinants of therapy response in ETV6::RUNX1 leukemia.
PubMed 文献 · Leukemia · 2025-07-09

该研究利用ETV6::RUNX1白血病的多组学数据,在疾病初诊时识别预测治疗反应的基因组特征。深度表征亚队列中发现快速反应者常伴APOBEC突变特征和高细胞周期活性基因表达特征,慢反应者中IGK基因重排更常见,并鉴定出与反应相关的突变和拷贝数变异。

要点

  • 快速反应者常伴APOBEC突变特征和高细胞周期活性基因表达特征
  • 慢反应者中IGK基因重排更频繁
  • 快速反应者chr12p臂缺失更频繁,慢反应者chr12短增益更常见

核心结论

  • 鉴定的遗传和转录组治疗敏感性标志物为初诊时改进疾病分类铺平道路,可能改善临床结局。

研究设计与样本

  • 研究利用ETV6::RUNX1白血病的多组学数据,在深度表征的亚队列中识别预测治疗反应的基因组特征。

主要发现

  • 快速反应病例频繁表现出APOBEC突变特征和高细胞周期活性的基因表达特征。
  • 慢反应者中IGK基因重排更频繁。
  • 鉴定出转录调节因子和肿瘤抑制基因(INTS1、NF1、TP53)中与反应相关的突变。
  • 拷贝数分析显示快速反应者chr12p臂缺失更频繁,导致影响诱导治疗反应相关基因(KRAS、FKBP4)的转录组变化,而慢反应者中chr12短增益更常见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETV6::RUNX1 leukemia is the second most common subtype of childhood B cell acute lymphoblastic leukemia (B-ALL). Although it generally has a low relapse risk, a significant proportion of B-ALL relapses occur within this subtype due to its relatively high incidence. Measurable residual disease at the end of induction therapy is a well-established biomarker predicting treatment outcomes, while no genomic biomarkers are routinely applied in clinics. In this study, we used multiomic data from ETV6::RUNX1 leukemias to identify genomic features predictive of therapy response at disease presentation. In the deeply characterized sub-cohort we discovered that fast-responding cases frequently exhibited the APOBEC mutational signature and the gene expression signature of high cell cycle activity. In contrast, rearrangements of IGK genes were more frequent in slow responders. Additionally, response-related mutations were identified in transcriptional regulators and tumor suppressor genes (INTS1, NF1, TP53). Copy number analysis revealed that fast responders harbored more frequent deletions of chr12 p-arm, leading to transcriptomic changes affecting genes associated with induction therapy response (KRAS, FKBP4), while a shorter gain in chr12 was more common in slow responders. The identified genetic and transcriptomic markers of treatment sensitivity pave the way for improved disease classification at presentation, potentially improving clinical outcomes.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Oksa L, Moisio S, Maqbool K, et al. Genomic determinants of therapy response in ETV6::RUNX1 leukemia. Leukemia. 2025. PMID: 40634509. doi:10.1038/s41375-025-02683-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。